Increased antipanic efficacy in combined treatment with clomipramine and dixyrazine.

Abstract

A double-blind 12 week trial was undertaken to compare the effects of clomipramine + dixyrazine with clomipramine + placebo in the treatment of panic disorder with or without agoraphobia. Of 45 patients included (21 dixyrazine, 24 placebo), 16 dropped out (6 dixyrazine, 10 placebo). The number of panic attacks and the scores on the panic disorder subscale of the Hamilton Anxiety Rating Scale were significantly reduced in response to both treatment regimens, but the reduction was significantly greater in the dixyrazine group. The patients' daily functioning was significantly more improved with the dixyrazine combination. The serum concentration of desmethylclomipramine monotherapy was significantly higher and the side effects significantly lower in the combined treatment with dixyrazine than with clomipramine monotherapy. Clomipramine combined with dixyrazine seems superior to clomipramine in the treatment of panic disorder.

• Authors: P O Feet, K G Götestam
• Journal: Acta psychiatrica Scandinavica (Acta Psychiatr Scand) Vol. 89 Issue 4 Pg. 230-4 (Apr 1994) ISSN: 0001-690X [Print] United States
• PMID: 7912879 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Phenothiazines
• Placebos
• desmethylclomipramine
• dixyrazine
• Clomipramine

Topics

• Adult
• Ambulatory Care
• Antipsychotic Agents (pharmacology, therapeutic use)
• Clomipramine (analogs & derivatives, blood, pharmacokinetics, therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Humans
• Male
• Panic Disorder (drug therapy, psychology)
• Phenothiazines (pharmacology, therapeutic use)
• Placebos
• Psychiatric Status Rating Scales
• Stimulation, Chemical
• Treatment Outcome